Sentiment Trading

Regeneron Pharmaceuticals Inc. saw its stock plummet 10% after a disappointing earnings report, driven by lower-than-expected demand for its flagship product Eylea, which is crucial to the company’s financial health.

Regeneron Pharmaceuticals Inc. made significant strides in the first quarter of 2025, with notable developments in oncology and ophthalmology, solidifying its position as a leader in the biotechnology industry.